Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.
Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E, Gkotzamanidou M, Migkou M, Gavriatopoulou M, Roussou M, Tasidou A, Dimopoulos MA. Kastritis E, et al. Leukemia. 2013 Apr;27(4):947-53. doi: 10.1038/leu.2012.309. Epub 2012 Nov 6. Leukemia. 2013. PMID: 23183429
Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease.
Kastritis E, Rousakis P, Kostopoulos IV, Gavriatopoulou M, Theodorakakou F, Fotiou D, Dialoupi I, Migkou M, Roussou M, Kanellias N, Tselegkidi MI, Eleutherakis-Papaiakovou E, Papanikolaou A, Gakiopoulou C, Psimenou E, Spyropoulou-Vlachou M, Gatou A, Terpos E, Tsitsilonis O, Dimopoulos MA. Kastritis E, et al. Among authors: spyropoulou vlachou m. Amyloid. 2021 Dec;28(4):259-266. doi: 10.1080/13506129.2021.1971192. Epub 2021 Sep 1. Amyloid. 2021. PMID: 34468250
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis.
Kastritis E, Fotiou D, Theodorakakou F, Dialoupi I, Migkou M, Roussou M, Karatrasoglou EA, Tselegkidi MI, Ntalianis A, Kanellias N, Eleutherakis-Papaiakovou E, Ntanasis-Stathopoulos I, Gakiopoulou C, Papanikolaou A, Papathoma A, Spyropoulou-Vlachou M, Psimenou E, Stamatelopoulos K, Gavriatopoulou M, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: spyropoulou vlachou m. Amyloid. 2021 Mar;28(1):3-11. doi: 10.1080/13506129.2020.1798224. Epub 2020 Jul 27. Amyloid. 2021. PMID: 32713209
Multiple Sclerosis and MEN2 Neoplasia in a Female Patient: A Unique Co-Existence with Expanded Immunological Interest and Therapeutical Challenges, before and after Patient's COVID-19 Infection.
Markoglou N, Simeakis G, Alevizaki M, Velonakis G, Chatzistamatiou T, Spyropoulou-Vlachou M, Stavropoulos-Giokas C, Stefanis L, Anagnostouli M. Markoglou N, et al. Among authors: spyropoulou vlachou m. Biomedicines. 2022 Nov 8;10(11):2850. doi: 10.3390/biomedicines10112850. Biomedicines. 2022. PMID: 36359367 Free PMC article.
HLA-genotyping by next-generation-sequencing reveals shared and unique HLA alleles in two patients with coexisting neuromyelitis optica spectrum disorder and thymectomized myasthenia gravis: Immunological implications for mutual aetiopathogenesis?
Vakrakou A, Chatzistamatiou T, Koros C, Karathanasis D, Tentolouris-Piperas V, Tzanetakos D, Stathopoulos P, Koutsis G, Spyropoulou-Vlachou M, Evangelopoulos ME, Stefanis L, Stavropoulos-Giokas C, Anagnostouli M. Vakrakou A, et al. Among authors: spyropoulou vlachou m. Mult Scler Relat Disord. 2022 Jul;63:103858. doi: 10.1016/j.msard.2022.103858. Epub 2022 May 8. Mult Scler Relat Disord. 2022. PMID: 35594634
Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy.
Terpos E, Kostopoulos IV, Kastritis E, Ntanasis-Stathopoulos I, Migkou M, Rousakis P, Argyriou AT, Kanellias N, Fotiou D, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Ziogas DC, Papanota AM, Spyropoulou-Vlachou M, Trougakos IP, Tsitsilonis OE, Paiva B, Dimopoulos MA. Terpos E, et al. Among authors: spyropoulou vlachou m. Hemasphere. 2019 Oct 1;3(6):e300. doi: 10.1097/HS9.0000000000000300. eCollection 2019 Dec. Hemasphere. 2019. PMID: 31976475 Free PMC article.
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
Kastritis E, Roussou M, Gavriatopoulou M, Kanellias N, Migkou M, Eleutherakis-Papaiakovou E, Ziogas DC, Fotiou D, Ntanasis-Stathopoulos I, Dialoupi I, Giannouli S, Tsirigotis P, Delimpasi S, Mparmparousi D, Spyropoulou-Vlachou M, Xirokosta A, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: spyropoulou vlachou m. Blood Adv. 2019 Dec 10;3(23):4095-4103. doi: 10.1182/bloodadvances.2019000539. Blood Adv. 2019. PMID: 31821457 Free PMC article.
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.
Kastritis E, Gavriatopoulou M, Roussou M, Bagratuni T, Migkou M, Fotiou D, Ziogas DC, Kanellias N, Eleutherakis-Papaiakovou E, Dialoupi I, Ntanasis-Stathopoulos I, Spyropoulou-Vlachou M, Psimenou E, Gakiopoulou H, Marinaki S, Papadopoulou E, Ntalianis A, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: spyropoulou vlachou m. Amyloid. 2018 Dec;25(4):234-241. doi: 10.1080/13506129.2018.1540410. Epub 2019 Jan 20. Amyloid. 2018. PMID: 30663408
28 results